Trial · NCT04197076
Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
NCT04197076, Unknown, Shanghai Chest Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB. Trials, record NCT04197076. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04197076
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer Stages IIB-IIIB
- NCT number
- NCT04197076
- Status
- Unknown
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Shanghai Chest Hospital
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- anti-PD-1 or anti-PD-L1, EGFR-TKI, ALK inhibitor, ROS1 inhibitor, investigator decided
- First posted
- 2019-12-12
- Last updated
- 2022-07-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | DFS: disease free survival | 36 months | The time length from randomization(mainly from the receipt of pathology and genetic diagnosis reports)to any of the following events: disease progression, disease recurrence or death from any cause. Disease progression or relapse will be assessed according to RECIST 1.1 |
| Primary | pCR: pathologic complete response | 36 months | the proportion of patients achieved pathologic complete response（lung and lymph node without tumor residual assessed by pathology review) |
| Secondary | OS: Overall survival | 36 months | The time length from the date of randomization (according to the received pathology and genetic diagnosis report) to the date of death. |
| Other | cRR rates | approximately 10 weeks After surgery | The proportion of patients achieved complete or patial remission(Imageological) according to RECIST 1.1 prior to definitive surgery |
| Other | Safty AEs | 36 months | proportion of delayed or cancelled surgery or duration of surgery or length of hospitalization or surgical procedure, and incidence of AE/SAE associated with surgery, Adverse events will be graded according to NCI CTCAE |
| Other | Qol Quality of Life | 36 months | Quality of life asscesed by Quality of Life Questionnare-Core 30(EORTC QLQ-C30）of The European O-rganization for Reasearch and Treatment of Cancer containing 30 items in total. Among them, items 29 and 30 are divided into seven grades. According to the answer options 1 to 7 points. Other items are divided into four grades: none, one point, some to many. When scoring, they are directly rated 1 to 4 points. For functional and overal health domain, higher score means better life quality; for symptom domain ,higher score means worse life quality. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04197076
GET https://conductscience.org/api/trials/v1/NCT04197076/registered